Xuanzhu Biopharmaceutical Joins Hang Seng Composite IndexXuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026

Reuters

02/22

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2613222177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613222177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613222177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-22 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613222177","market":"us","top_or_hot":-1,"title":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      **Xuanzhu Biopharmaceutical Joins <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the <a href=\"https://laohu8.com/S/HSNGY\">Hang Seng</a> Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260222-12027158), on February 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-22 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      **Xuanzhu Biopharmaceutical Joins <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the <a href=\"https://laohu8.com/S/HSNGY\">Hang Seng</a> Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260222-12027158), on February 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL2nmBT7:1","article_id":"2613222177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613222177","pubTimestamp":1771754767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026. Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","BK1600":"工业大麻","00460":"四环医药","02575":"轩竹生物-B","BK1191":"制药","BK1515":"抗疫概念"},"translate_title":"**轩竹生物制药加入恒生综合指数**轩竹生物制药有限公司表示，将在恒生指数季度检讨后被纳入恒生综合指数成分股，该变动于2026年3月9日生效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9,"02575":0.9},"content_text":"**Xuanzhu Biopharmaceutical Joins <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the <a href=\"https://laohu8.com/S/HSNGY\">Hang Seng</a> Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026\n    \n\n        Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260222-12027158), on February 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"}}}